Vimarsana
Biggest News Aggregation in the World

Page 2 - Advanced Prostate News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Advanced Prostate. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Advanced Prostate Today - Breaking & Trending Today

Global Cancer Therapies Strategic Business Report 2023: Industry Focuses on New Approaches to Treat Cancer - Vimarsana News

Global Cancer Therapies Strategic Business Report 2023: Industry Focuses on New Approaches to Treat Cancer

/PRNewswire/ -- The "Cancer Therapies: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. Global Cancer Therapies...

LYNPARZA® (olaparib) plus abiraterone approved in the US for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer - Vimarsana News

LYNPARZA® (olaparib) plus abiraterone approved in the US for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer

LYNPARZA combination reduced the risk of disease progression or death by 76% vs. abiraterone alone First PARP inhibitor approved in combination with a novel hormonal agent underscores clinically... | June 1, 2023

New Research in JNCCN Highlights the Negative Impact of Continued Exclusion of Racial Groups from Research on Cancer Genomics USA - Vimarsana News

New Research in JNCCN Highlights the Negative Impact of Continued Exclusion of Racial Groups from Research on Cancer Genomics USA

Researchers call for better inclusion of people in Africa and with African ancestry in studies on inherited genetics to help address disparities in prostate cancer outcomes.

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Lynparza approved in EU for prostate cancer - Vimarsana News

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Lynparza approved in EU for prostate cancer

Investegate announcements from AstraZeneca PLC, Lynparza approved in EU for prostate cancer

Novartis Pharma AG: Novartis PluvictoTM shows statistically significant and clinically meaningful radiographic progression-free survival benefit in patients with PSMA-positive metastatic castration-resistant prostate cancer - Vimarsana News

Novartis Pharma AG: Novartis PluvictoTM shows statistically significant and clinically meaningful radiographic progression-free survival benefit in patients with PSMA-positive metastatic castration-resistant prostate cancer

Ad hoc announcement pursuant to Art. 53 LR Phase III PSMAfore trial with PluvictoTM met the primary endpoint of radiographic progression-free survival (rPFS) in PSMA-positive mCRPC who have been treated